Trinity Delta £20m raise funds commercialisation through to mid-2024

£20m raise funds commercialisation through to mid-2024

Lighthouse | 15 July 2022

Share this note

ANGLE has successfully raised £20m (gross) through a placing of 25.2m new shares, representing c 10.7% of the share capital, through a combination of an institutional placing, a retail offer, and management subscription. The placing price was 80p, a discount of 14.4% on the previous closing price. The quality of new and existing institutions supporting the raise, achieved during notably challenging market conditions, is a testament to the strength of the investment case.
The funds, together with existing resources and revenues from current activities, will support the plans to establish Parsortix as the clear leader in harvesting CTCs (circulating tumour cells) for analysis. FDA approval for capturing intact CTCs in metastatic breast cancer (mBC) marked a key transition point, opening numerous clinical opportunities across multiple diagnostic applications. Management’s challenge is addressing these wide-ranging potential uses in a systematic, effective, and efficient manner.
A multi-pronged strategy is being employed, with near-term revenue generated from a growing pharma services business and longer-term opportunities being addressed through the supply of instruments and cassettes into the clinical market for patient management. The marketing and promotional activities have already begun, with an element of the new funds targeted to broadening these further.
In parallel, a series of Laboratory Developed Tests (LDTs) are being created within ANGLE’s clinical laboratories, which should act as important demonstrators of Parsortix’s utility and accelerators of market awareness, appropriate reimbursement codes, and adoption among the clinical customer base.
The first LDT is an assay that accurately differentiates between a benign mass and ovarian cancer, allowing women with an abnormal pelvic mass to be triaged to the appropriate treatment. These tests, coupled with the FDA approval in mBC and the growing body of peer-reviewed scientific evidence, are expected to position Parsortix as a key tool to not only accurately identify tumours but also to guide the treatment pathway.

Trinity Delta view: The FDA clearance of the Parsortix system in mBC was a major turning point for ANGLE, providing gold standard validation of the unrivalled flexibility, consistency, and clinical insights it provides. The challenge now shifts to maximising industry awareness and capitalising on the multiple clinical opportunities. Management is pursuing a well-articulated strategy addressing a number of distinct diagnostic segments, with both near- and longer-term objectives. This equity raise removes financial uncertainty and allows, on our conservative forecasts, these marketing and commercialisation plans to be funded through to mid-2024. Our ANGLE valuation is £506m ($658m), which would be equivalent to 194p/share based on the increased number of shares, with significant upside once Parsortix’s positioning becomes clearer.

Lighthouse

15 July 2022


Price	93.50p
Market Cap	£193.3m
Primary exchange	AIM London
Sector	Healthcare
Company Code	AGL

Corporate client	Yes

Company description

ANGLE is a specialist diagnostics company. Its proprietary Parsortix technology can capture and harvest very rare cells, including CTCs (circulating tumour cells), from a blood sample. The FDA approval for its clinical use to guide precision cancer care will open up further multiple commercial opportunities.

Analysts

Lala Gregorek
lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Franc Gregori
fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.